HU226521B1 - Novel crystalmodification of cdch, process for producing it and pharmaceutical composition containing it - Google Patents

Novel crystalmodification of cdch, process for producing it and pharmaceutical composition containing it Download PDF

Info

Publication number
HU226521B1
HU226521B1 HU9603428A HUP9603428A HU226521B1 HU 226521 B1 HU226521 B1 HU 226521B1 HU 9603428 A HU9603428 A HU 9603428A HU P9603428 A HUP9603428 A HU P9603428A HU 226521 B1 HU226521 B1 HU 226521B1
Authority
HU
Hungary
Prior art keywords
cdch
monohydrate
anhydrous
crystalline
water
Prior art date
Application number
HU9603428A
Other languages
English (en)
Hungarian (hu)
Inventor
Patrick Dr Bosche
Alfons Dr Grunenberg
Original Assignee
Bayer Healthcare Ag
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=7779831&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=HU226521(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Bayer Healthcare Ag filed Critical Bayer Healthcare Ag
Publication of HU9603428D0 publication Critical patent/HU9603428D0/hu
Publication of HUP9603428A2 publication Critical patent/HUP9603428A2/hu
Publication of HUP9603428A3 publication Critical patent/HUP9603428A3/hu
Publication of HU226521B1 publication Critical patent/HU226521B1/hu

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Oncology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
HU9603428A 1995-12-12 1996-12-12 Novel crystalmodification of cdch, process for producing it and pharmaceutical composition containing it HU226521B1 (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
DE19546249A DE19546249A1 (de) 1995-12-12 1995-12-12 Neue Kristallmodifikation des 1-Cyclopropyl-7-([S,S]-2,8-diazabicyclo[4,3,0]non-8-yl)-6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäure Hydrochlorid (CDCH), Verfahren zu dessen Herstellung und diese enthaltende pharmazeutische Zubereitungen

Publications (4)

Publication Number Publication Date
HU9603428D0 HU9603428D0 (en) 1997-01-28
HUP9603428A2 HUP9603428A2 (en) 1997-08-28
HUP9603428A3 HUP9603428A3 (en) 1997-10-28
HU226521B1 true HU226521B1 (en) 2009-03-30

Family

ID=7779831

Family Applications (1)

Application Number Title Priority Date Filing Date
HU9603428A HU226521B1 (en) 1995-12-12 1996-12-12 Novel crystalmodification of cdch, process for producing it and pharmaceutical composition containing it

Country Status (42)

Country Link
US (1) US5849752A (enExample)
EP (1) EP0780390B1 (enExample)
JP (1) JP4104687B2 (enExample)
KR (1) KR100525146B1 (enExample)
CN (1) CN1061348C (enExample)
AR (1) AR005009A1 (enExample)
AT (1) ATE221531T1 (enExample)
AU (1) AU708006B2 (enExample)
BG (1) BG62258B1 (enExample)
BR (1) BR9605968A (enExample)
CA (1) CA2192418C (enExample)
CO (1) CO4480105A1 (enExample)
CU (1) CU22774A3 (enExample)
CZ (1) CZ288657B6 (enExample)
DE (2) DE19546249A1 (enExample)
DK (1) DK0780390T3 (enExample)
EE (1) EE03474B1 (enExample)
ES (1) ES2179910T3 (enExample)
HR (1) HRP960558B1 (enExample)
HU (1) HU226521B1 (enExample)
ID (1) ID22625A (enExample)
IL (1) IL119795A (enExample)
IN (1) IN185805B (enExample)
MA (1) MA24342A1 (enExample)
MY (1) MY117492A (enExample)
NL (1) NL300109I1 (enExample)
NO (1) NO306725B1 (enExample)
NZ (1) NZ299905A (enExample)
PL (1) PL184885B1 (enExample)
PT (1) PT780390E (enExample)
RO (1) RO119782B1 (enExample)
RU (1) RU2162468C2 (enExample)
SA (1) SA96170492B1 (enExample)
SG (1) SG47201A1 (enExample)
SI (1) SI0780390T1 (enExample)
SK (1) SK282805B6 (enExample)
SV (1) SV1996000109A (enExample)
TR (1) TR199600970A2 (enExample)
TW (1) TW411340B (enExample)
UA (1) UA35638C2 (enExample)
YU (1) YU49485B (enExample)
ZA (1) ZA9610405B (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
HU226583B1 (hu) * 1997-09-25 2009-04-28 Bayer Ag Moxifloxacint tartalmazó szabályozott hatóanyag-leadású gyógyászati készítmények
DE19751948A1 (de) * 1997-11-24 1999-05-27 Bayer Ag Verfahren zur Herstellung von 8-Methoxy-Chinoloncarbonsäuren
US6395746B1 (en) 1998-09-30 2002-05-28 Alcon Manufacturing, Ltd. Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
US6509327B1 (en) 1998-09-30 2003-01-21 Alcon Manufacturing, Ltd. Compositions and methods for treating otic, ophthalmic and nasal infections
US6716830B2 (en) 1998-09-30 2004-04-06 Alcon, Inc. Ophthalmic antibiotic compositions containing moxifloxacin
KR100650489B1 (ko) * 1998-11-10 2006-11-28 바이엘 헬스케어 아게 목시플록사신 제약 제제
DE19854357A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Semi-Hydrochlorid von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo/4.3.0/ -nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854355A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation B von 8-Cyan-1-cyclopropyl-7-(1S, 6S-2,8-diazabicyclo-/4.3.O/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19854356A1 (de) * 1998-11-25 2000-05-31 Bayer Ag Kristallmodifikation A von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo-/4.3.0/nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE19908449A1 (de) 1999-02-26 2000-08-31 Bayer Ag Kristallmodifikation C von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicylo-[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chino/incarbonsäure
WO2004039804A1 (en) * 2002-10-31 2004-05-13 Ranbaxy Laboratories Limited Amorphous moxifloxacin hydrochloride
EP1615645B2 (en) † 2003-04-09 2013-08-21 Dr. Reddy's Laboratories Ltd. A crystalline form iii of anhydrous moxifloxacin hydrochloride and a process for the preparation thereof
WO2005012285A1 (en) * 2003-08-05 2005-02-10 Matrix Laboratories Ltd An improved process for the preparation of moxifloxacin hydrochloride
ITMI20032259A1 (it) 2003-11-20 2005-05-21 Chemi Spa Nuovo polimorfo dell'acido 1-ciclopropil-7-(s,s-2,8-diazabciclo-4.3.0-non-8-il)-6-fluoro-1,4-diidro-8-metossi-4-oxo-chinolin carbossilico cloridrato e metodi per la sua preparazione
DE602004018370D1 (de) * 2003-11-20 2009-01-22 Chemi Spa Polymorphe von 1-cyclopropyl-7-(äs,sü - 2,8-diazadicyclo ä4.3.0ü non-8-yl) -6-fluor-1,4-dihydro-8-methoxy-4-oxo-3-chinolincarbonsäurehydrochlorid und verfahren zu deren herstellung
US7491725B2 (en) 2004-02-06 2009-02-17 Bristol-Myers Squibb Company Process for preparing 2-aminothiazole-5-aromatic carboxamides as kinase inhibitors
DE102004015981A1 (de) * 2004-04-01 2005-10-20 Bayer Healthcare Ag Neue kirstalline Form von 8-Cyan-1-cyclopropyl-7-(1S,6S-2,8-diazabicyclo[4.3.0]nonan-8-yl)-6-fluor-1,4-dihydro-4-oxo-3-chinolincarbonsäure
DE102004063347A1 (de) * 2004-12-23 2006-07-13 Stada Arzneimittel Ag Gebrauchsfertige Gemcitabinlösungen und Gemcitabinlösungskonzentrate
WO2007033515A1 (fr) * 2005-09-21 2007-03-29 Shenzhen Tys R & D Co., Ltd. Formulation orale contenant de la moxifloxacine et son procédé de préparation
GB0612422D0 (en) * 2006-06-23 2006-08-02 Generics Uk Ltd Novel hydrate form
AU2007264030B2 (en) 2006-06-27 2012-04-05 Sandoz Ag New method for salt preparation
ES2303768B1 (es) * 2006-09-08 2009-06-05 Quimica Sintetica, S.A. Nueva forma cristalina de moxifloxacino clorhidrato.
KR20150048920A (ko) 2006-11-13 2015-05-07 씨아이피엘에이 엘티디. 목시플록사신 염산염의 합성방법
EP1992626A1 (en) * 2007-05-10 2008-11-19 Sandoz AG Process for the preparation of moxifloxacin hydrochloride
EP2083010A1 (en) * 2008-01-08 2009-07-29 Chemo Ibérica, S.A. Polymorphic Forms of Moxifloxacin hydrochloride and processes for preparation thereof
EP2154137A1 (en) 2008-08-04 2010-02-17 Chemo Ibérica, S.A. Crystalline form of moxifloxacin base
TR201106844T2 (tr) 2008-10-09 2012-02-21 Abd� �Brah�M �La� Sanay� Ve T�Caret Anon�M ��Rket�@ Moksi̇floksasi̇n yaş granülasyonunda organi̇k solventleri̇n kullanimi.
EP2342204A1 (en) * 2008-11-06 2011-07-13 Hetero Research Foundation Novel polymorph of moxifloxacin hydrochloride
EP2364141B2 (de) 2008-12-08 2017-08-02 ratiopharm GmbH Kompaktiertes moxifloxacin
NZ610978A (en) 2009-05-15 2014-11-28 Redx Pharma Ltd Redox drug derivatives
WO2011121596A2 (en) * 2010-04-01 2011-10-06 Neuland Laboratories Ltd. Crystal modification of moxifloxacin hydrochloride
BRPI1106900A2 (pt) 2011-12-26 2013-11-05 Ems Sa Composição farmacêutica sólida compreendendo antibótico da familia das quinolonas e processo de sua obtenção
FR2992218B1 (fr) 2012-06-22 2015-01-23 Rivopharm Sa Composition pharmaceutique de chlorhydrate de moxifloxacine et procede de preparation
CN102924449B (zh) * 2012-10-30 2015-08-12 重庆福安药业集团庆余堂制药有限公司 盐酸莫西沙星h晶型及其制备方法和药物组合物
WO2014087292A1 (en) 2012-12-04 2014-06-12 Mankind Research Centre An improved process for the preparation of moxifloxacin hydrochloride
RU2561037C2 (ru) * 2013-02-07 2015-08-20 Открытое акционерное общество "Химико-фармацевтический комбинат "АКРИХИН" (ОАО "АКРИХИН") Антибактериальная фармацевтическая композиция и способ ее получения
CA2904387C (en) 2013-03-15 2021-12-07 Melinta Therapeutics, Inc. Methods of treating infections in overweight and obese patients using antibiotics

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE3601567A1 (de) * 1986-01-21 1987-07-23 Bayer Ag 7-(azabicycloalkyl)-chinoloncarbonsaeure- und -naphthyridon-carbonsaeure-derivate
FI871419L (fi) * 1986-03-31 1987-10-01 Sankyo Co Kinolin-3-karboxylsyraderivat, deras framstaellning och anvaendning.
AU609974B2 (en) * 1988-05-18 1991-05-09 Warner-Lambert Company Improved process for the preparation of 5-amino-7- (substituted amino)-quinoline-3-carboxylic acids
DE3910663A1 (de) * 1989-04-03 1990-10-04 Bayer Ag 5-alkylchinoloncarbonsaeuren
RO108347B1 (ro) * 1989-10-30 1994-04-28 Bellon Labor Sa Roger DERIVATI DE BENZO-(b)-NAFTIRIDIN-1,8 SI PROCEDEU DE PREPARARE A ACESTORA
TW209865B (enExample) 1992-01-10 1993-07-21 Bayer Ag
WO1993015070A1 (fr) * 1992-01-31 1993-08-05 Chugai Seiyaku Kabushiki Kaisha Cristal d'hydrate de derive d'acide quinolonecarboxylique
DE4234078A1 (de) * 1992-10-09 1994-04-14 Bayer Ag Chinoloncarbonsäuren
JP3268098B2 (ja) * 1992-12-25 2002-03-25 第一製薬株式会社 二環性環状アミン誘導体
ZA946853B (en) * 1993-09-10 1995-04-24 Daiichi Seiyaku Co Crystals of antimicrobial compound.
EP0676199B1 (en) * 1994-04-07 1998-09-02 Pfizer Inc. Use of trovafloxacin or derivatives thereof for the manufacture of a medicament for the treatment of H. pylori infections

Also Published As

Publication number Publication date
SK159196A3 (en) 1997-10-08
CU22774A3 (es) 2002-07-24
HRP960558A2 (en) 1998-02-28
SG47201A1 (en) 1998-03-20
PL184885B1 (pl) 2003-01-31
KR970042550A (ko) 1997-07-24
CZ288657B6 (cs) 2001-08-15
CO4480105A1 (es) 1997-07-09
KR100525146B1 (ko) 2006-01-27
NO306725B1 (no) 1999-12-13
ZA9610405B (en) 1997-06-23
EE9600201A (et) 1997-06-16
BR9605968A (pt) 1998-08-18
EE03474B1 (et) 2001-08-15
SA96170492B1 (ar) 2006-05-23
ID22625A (id) 1999-12-02
SV1996000109A (es) 1997-10-23
HU9603428D0 (en) 1997-01-28
NZ299905A (en) 1998-09-24
CA2192418C (en) 2001-06-12
CA2192418A1 (en) 1997-06-13
YU49485B (sh) 2006-08-17
PL317415A1 (en) 1997-06-23
US5849752A (en) 1998-12-15
IL119795A (en) 1998-12-27
UA35638C2 (uk) 2001-04-16
EP0780390B1 (de) 2002-07-31
DK0780390T3 (da) 2002-11-11
JP4104687B2 (ja) 2008-06-18
IL119795A0 (en) 1997-03-18
PT780390E (pt) 2002-11-29
CZ364696A3 (en) 1997-07-16
HUP9603428A3 (en) 1997-10-28
NO965298D0 (no) 1996-12-11
YU65096A (sh) 1998-12-23
ATE221531T1 (de) 2002-08-15
MA24342A1 (fr) 1998-07-01
DE59609501D1 (de) 2002-09-05
SK282805B6 (sk) 2002-12-03
BG101043A (en) 1998-04-30
RO119782B1 (ro) 2005-03-30
TW411340B (en) 2000-11-11
MX9606325A (es) 1997-10-31
AU7421696A (en) 1997-06-19
ES2179910T3 (es) 2003-02-01
CN1160052A (zh) 1997-09-24
IN185805B (enExample) 2001-05-05
TR199600970A2 (tr) 1997-06-21
HUP9603428A2 (en) 1997-08-28
EP0780390A1 (de) 1997-06-25
JPH09169757A (ja) 1997-06-30
SI0780390T1 (en) 2002-10-31
RU2162468C2 (ru) 2001-01-27
BG62258B1 (bg) 1999-06-30
CN1061348C (zh) 2001-01-31
NL300109I1 (nl) 2003-02-03
NO965298L (no) 1997-06-13
DE19546249A1 (de) 1997-06-19
AR005009A1 (es) 1999-04-07
MY117492A (en) 2004-07-31
HRP960558B1 (en) 2002-04-30
AU708006B2 (en) 1999-07-29

Similar Documents

Publication Publication Date Title
HU226521B1 (en) Novel crystalmodification of cdch, process for producing it and pharmaceutical composition containing it
RU2270200C2 (ru) Полиморфные формы рифаксимина, способы их получения и их применение в медицинских препаратах
KR100207802B1 (ko) N-[4-(5-시클로펜틸옥시카르보닐)아미노-1-메틸인돌-3-일-메틸]-3-메톡시벤조일]-2-메틸벤젠설폰아미드 화합물 및 이것의 제조 방법
CA2350956C (en) New crystals of celecoxib
KR20010074472A (ko) 신규의 결정질 형태의 항바이러스성 벤즈이미다졸 화합물
RU2125571C1 (ru) СОЛЬ 7-([1α,5α,6α]-6-АМИНО-3-АЗАБИЦИКЛО [3.1.0] ГЕКС-3-ИЛ)-6-ФТОР-1-(2,4-ДИФТОРФЕНИЛ)-1,4- ДИГИДРО-4-ОКСО-1,8-НАФТИРИДИН-3-КАРБОНОВОЙ И МЕТАНСУЛЬФОНОВОЙ КИСЛОТ И СПОСОБ ЕЕ ПОЛУЧЕНИЯ
JP3726291B2 (ja) 安定な結晶構造を有するベンゾオキサジン化合物およびその製造法
HU195778B (en) Process for producing stabil modifications of torasemid and pharmaceutical compositions containing them
AU679094B2 (en) Crystals of antimicrobial compound
PL194752B1 (pl) Krystaliczna postać VI 5,6-dichloro-2-(izopropyloamino)-1-(ß-L-rybofuranozylo)-1H-benzimidazolu, sposób jej wytwarzania, kompozycja farmaceutyczna zawierająca krystaliczną postać i zastosowanie krystalicznej postaci
SK15032000A3 (sk) Maleínan paroxetínu, spôsob jeho výroby a jeho použitie
KR20020010688A (ko) 결정질 아자비시클로(2,2,2)옥탄-3-아민 시트레이트의다형체 및 그의 제약 조성물
KR101561963B1 (ko) 세프디토렌 피복실의 신규 결정 형태 및 이의 제조 방법
HK1002006A (en) Crystalline modification of cdch, process for its preparation and pharmaceutical compositions containing it
HK1002006B (en) Crystalline modification of cdch, process for its preparation and pharmaceutical compositions containing it
HK1235765B (en) Medicaments containing crystalline modifications of (1r,2r)-3-(3-dimethylamino-1-ethyl-2-methyl-propyl)-phenol
HK1046284B (en) Polymorphs of crystalline azabicyclo(2,2,2) octan-3-aminecitrate and their pharmaceutical compositions
HU226912B1 (en) New paroxetin salt and medicament containing it

Legal Events

Date Code Title Description
GB9A Succession in title

Owner name: BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE

Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE

GB9A Succession in title

Owner name: BAYER INTELLECTUAL PROPERTY GMBH, DE

Free format text: FORMER OWNER(S): BAYER AG., DE; BAYER HEALTHCARE AG., DE; BAYER SCHERING PHARMA AKTIENGESELLSCHAFT, DE